Skip to main content
Erschienen in: Journal of Radiation Oncology 1/2018

06.09.2017 | Original Research

The dosimetric effects of limited elective nodal irradiation in volumetric modulated arc therapy treatment planning for locally advanced non-small cell lung cancer

Erschienen in: Journal of Radiation Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

Contemporary radiotherapy guidelines for locally advanced non-small cell lung carcinoma (LA-NSCLC) recommend omitting elective nodal irradiation, despite the fact that evidence supporting this came primarily from older reports assessing comprehensive nodal coverage using 3D conformal techniques. Herein, we evaluated the dosimetric implications of the addition of limited elective nodal irradiation (LENI) to standard involved field irradiation (IFI) using volumetric modulated arc therapy (VMAT) planning.

Method

Target volumes and organs-at-risk (OARs) were delineated on CT simulation images of 20 patients with LA-NSCLC. Two VMAT plans (IFI and LENI) were generated for each patient. Involved sites were treated to 60 Gy in 30 fractions for both IFI and LENI plans. Adjacent uninvolved nodal regions, considered high risk based on the primary tumor site and extent of nodal involvement, were treated to 51 Gy in 30 fractions in LENI plans using a simultaneous integrated boost approach.

Results

All planning objectives for PTVs and OARs were achieved for both IFI and LENI plans. LENI resulted in significantly higher esophagus D mean (15.3 vs. 22.5 Gy, p < 0.01), spinal cord D max (34.9 vs. 42.4 Gy, p = 0.02) and lung D mean (13.5 vs. 15.9 Gy, p = 0.02), V 20 (23.0 vs. 27.9%, p = 0.03), and V 5 (52.6 vs. 59.4%, p = 0.02). No differences were observed in heart parameters. On average, only 32.2% of the high-risk nodal volume received an incidental dose of 51 Gy when untargeted in IFI plans.

Conclusion

The addition of LENI to VMAT plans for LA-NSCLC is feasible, with only modestly increased doses to OARs and marginal expected increase in associated toxicity.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat National Comprehensive Cancer Network® (NCCN) (2017) Practice guidelines in oncology: non-small cell lung cancer, Version 4. www.nccn.org National Comprehensive Cancer Network® (NCCN) (2017) Practice guidelines in oncology: non-small cell lung cancer, Version 4. www.​nccn.​org
2.
Zurück zum Zitat Belderbos JS, Kepka L, Spring Kong FM, Martel MK, Videtic GM, Jeremic B (2008) Report from the International Atomic Energy Agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer: non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 72(2):335–342PubMedCrossRef Belderbos JS, Kepka L, Spring Kong FM, Martel MK, Videtic GM, Jeremic B (2008) Report from the International Atomic Energy Agency (IAEA) consultants’ meeting on elective nodal irradiation in lung cancer: non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 72(2):335–342PubMedCrossRef
3.
Zurück zum Zitat Emami B, Mirkovic N, Scott C et al (2003) The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer 41(2):207–214PubMedCrossRef Emami B, Mirkovic N, Scott C et al (2003) The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer 41(2):207–214PubMedCrossRef
4.
Zurück zum Zitat De Ruysscher D, Wanders S, van Haren E et al (2005) Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62(4):988–994PubMedCrossRef De Ruysscher D, Wanders S, van Haren E et al (2005) Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62(4):988–994PubMedCrossRef
5.
Zurück zum Zitat Rosenzweig KE, Sura S, Jackson A, Yorke E (2007) Involved-field radiation therapy for inoperable non-small-cell lung cancer. J Clin Oncol 25(35):5557–5561PubMedCrossRef Rosenzweig KE, Sura S, Jackson A, Yorke E (2007) Involved-field radiation therapy for inoperable non-small-cell lung cancer. J Clin Oncol 25(35):5557–5561PubMedCrossRef
6.
Zurück zum Zitat Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY (2009) Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 4:5PubMedPubMedCentralCrossRef Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY (2009) Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 4:5PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Sanuki-Fujimoto N, Sumi M et al (2009) Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses. Radiother Oncol 91(3):433–437PubMedCrossRef Sanuki-Fujimoto N, Sumi M et al (2009) Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses. Radiother Oncol 91(3):433–437PubMedCrossRef
8.
Zurück zum Zitat Yuan S, Sun X, Li M et al (2007) A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 30(3):239–244PubMedCrossRef Yuan S, Sun X, Li M et al (2007) A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 30(3):239–244PubMedCrossRef
9.
Zurück zum Zitat Chen M, Bao Y, Ma HL et al (2013) Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study. Biomed Res Int 2013:371819PubMedPubMedCentral Chen M, Bao Y, Ma HL et al (2013) Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study. Biomed Res Int 2013:371819PubMedPubMedCentral
10.
Zurück zum Zitat Ahmed I, DeMarco M, Stevens CW, Fulp WJ, Dilling TJ (2011) Analysis of incidental radiation dose to uninvolved mediastinal/supraclavicular lymph nodes in patients with limited-stage small cell lung cancer treated without elective nodal irradiation. Med Dosim 36(4):440–447PubMedCrossRef Ahmed I, DeMarco M, Stevens CW, Fulp WJ, Dilling TJ (2011) Analysis of incidental radiation dose to uninvolved mediastinal/supraclavicular lymph nodes in patients with limited-stage small cell lung cancer treated without elective nodal irradiation. Med Dosim 36(4):440–447PubMedCrossRef
11.
Zurück zum Zitat Kepka L, Bujko K, Zolciak-Siwinska A, Garmol D (2008) Incidental irradiation of mediastinal and hilar lymph node stations during 3D-conformal radiotherapy for non-small cell lung cancer. Acta Oncol 47(5):954–961PubMedCrossRef Kepka L, Bujko K, Zolciak-Siwinska A, Garmol D (2008) Incidental irradiation of mediastinal and hilar lymph node stations during 3D-conformal radiotherapy for non-small cell lung cancer. Acta Oncol 47(5):954–961PubMedCrossRef
12.
Zurück zum Zitat Kong FM, Cuneo KC, Wang L et al Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology. Pract Radiat Oncol 4(2):e133–e141 Kong FM, Cuneo KC, Wang L et al Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology. Pract Radiat Oncol 4(2):e133–e141
13.
Zurück zum Zitat Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199PubMedPubMedCentralCrossRef Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Kanzaki R, Higashiyama M, Fujiwara A et al (2011) Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: risk factors, pattern, and histopathological study. Lung Cancer 71(3):333–337PubMedCrossRef Kanzaki R, Higashiyama M, Fujiwara A et al (2011) Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: risk factors, pattern, and histopathological study. Lung Cancer 71(3):333–337PubMedCrossRef
15.
Zurück zum Zitat Cerfolio RJ, Bryant AS (2008) Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 86(2):362–366 discussion 366-367PubMedCrossRef Cerfolio RJ, Bryant AS (2008) Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 86(2):362–366 discussion 366-367PubMedCrossRef
16.
Zurück zum Zitat Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H (1999) Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg 16(Suppl 1):S17–S24PubMedCrossRef Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H (1999) Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg 16(Suppl 1):S17–S24PubMedCrossRef
17.
Zurück zum Zitat Kotoulas CS, Foroulis CN, Kostikas K et al (2004) Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer 44(2):183–191PubMedCrossRef Kotoulas CS, Foroulis CN, Kostikas K et al (2004) Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer 44(2):183–191PubMedCrossRef
18.
19.
Zurück zum Zitat Dunant A, Pignon JP, De Ruysscher D, et al (2006) Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement (Lung Art) Dunant A, Pignon JP, De Ruysscher D, et al (2006) Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement (Lung Art)
20.
Zurück zum Zitat Kim JH, van Beek EJ, Murchison JT, Marin A, Mirsadraee S (2015) The International Association for the Study of Lung Cancer lymph node map: a radiologic atlas and review. Tuberc Respir Dis (Seoul) 78(3):180–189CrossRef Kim JH, van Beek EJ, Murchison JT, Marin A, Mirsadraee S (2015) The International Association for the Study of Lung Cancer lymph node map: a radiologic atlas and review. Tuberc Respir Dis (Seoul) 78(3):180–189CrossRef
21.
Zurück zum Zitat Kong FM, Galvin J, Haken RT, Machtay M, Bradley J (2017) RTOG Foundation Inc. Contouring atlas Kong FM, Galvin J, Haken RT, Machtay M, Bradley J (2017) RTOG Foundation Inc. Contouring atlas
22.
Zurück zum Zitat Marks LB, Yorke ED, Jackson A et al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76(3 Suppl):S10–S19PubMedPubMedCentralCrossRef Marks LB, Yorke ED, Jackson A et al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76(3 Suppl):S10–S19PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Graham MV, Purdy JA, Emami B et al (1999) Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45(2):323–329PubMedCrossRef Graham MV, Purdy JA, Emami B et al (1999) Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45(2):323–329PubMedCrossRef
24.
Zurück zum Zitat Bernard ME, Glaser SM, Gill BS et al (2017) Results of a single institution experience with dose-escalated chemoradiation for locally advanced unresectable non-small cell lung cancer. Front Oncol 7:1PubMedPubMedCentralCrossRef Bernard ME, Glaser SM, Gill BS et al (2017) Results of a single institution experience with dose-escalated chemoradiation for locally advanced unresectable non-small cell lung cancer. Front Oncol 7:1PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Kharofa J, Gore E (2013) Symptomatic radiation pneumonitis in elderly patients receiving thoracic irradiation. Clin Lung Cancer 14(3):283–287PubMedCrossRef Kharofa J, Gore E (2013) Symptomatic radiation pneumonitis in elderly patients receiving thoracic irradiation. Clin Lung Cancer 14(3):283–287PubMedCrossRef
26.
Zurück zum Zitat Qiao W-B, Zhao Y-H, Zhao Y-B, Wang R-Z (2005) Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity. World J Gastroenterol 11(17):2626–2629PubMedPubMedCentralCrossRef Qiao W-B, Zhao Y-H, Zhao Y-B, Wang R-Z (2005) Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity. World J Gastroenterol 11(17):2626–2629PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Bradley J, Deasy JO, Bentzen S, El-Naqa I (2004) Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 58(4):1106–1113PubMedCrossRef Bradley J, Deasy JO, Bentzen S, El-Naqa I (2004) Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 58(4):1106–1113PubMedCrossRef
28.
Zurück zum Zitat Vielva LR, Jaen MW, Alcacer JA, Cardona MC (2014) State of the art in surgery for early stage NSCLC—does the number of resected lymph nodes matter? Transl Lung Cancer Res 3(2):95–99PubMedPubMedCentral Vielva LR, Jaen MW, Alcacer JA, Cardona MC (2014) State of the art in surgery for early stage NSCLC—does the number of resected lymph nodes matter? Transl Lung Cancer Res 3(2):95–99PubMedPubMedCentral
Metadaten
Titel
The dosimetric effects of limited elective nodal irradiation in volumetric modulated arc therapy treatment planning for locally advanced non-small cell lung cancer
Publikationsdatum
06.09.2017
Erschienen in
Journal of Radiation Oncology / Ausgabe 1/2018
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-017-0327-2

Weitere Artikel der Ausgabe 1/2018

Journal of Radiation Oncology 1/2018 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.